BostonSight

BostonSight BostonSight is a nonprofit that advances the treatment of diseased or damaged corneas and dry eye. Prasad Eye Institute in the Middle East and India.

BostonSight restores sight and improves the quality of life for individuals with ocular surface disease. We developed Prosthetic Replacement of the Ocular Surface Ecosystem (PROSE)™, a medical treatment to improve visual function for those suffering from complex corneal disease. During treatment, PROSE Clinical Fellows custom design FDA-cleared prosthetic devices to replace or support damaged ocular functions, improving vision and reducing pain and light sensitivity. For many patients, BostonSight PROSE™ treatment is their only option to restore their vision and end the suffering from critical and devastating eye issues. BostonSight PROSE treatment is available at top medical centers around the U.S., Canada, and India. Find a PROSE provider at http://www.bostonsight.org/find-a-provider/. BostonSight SCLERAL was launched to expand access to global scleral lens technology. Eye care practitioners can achieve an effective scleral lens fit that provides optimal vision and comfort for patients while attaining long-term eye health. BostonSight SCLERAL has partnerships around the world: ABB Optical in North America, Spectrum International in Latin America, and L.V.

Have you ever wondered about PROSE® treatment and how it might help you? PROSE (prosthetic replacement of the ocular sur...
02/25/2026

Have you ever wondered about PROSE® treatment and how it might help you? PROSE (prosthetic replacement of the ocular surface ecosystem) is a treatment pioneered by BostonSight. For thousands of patients suffering from the most complex ocular surface diseases, including keratoconus, dry eye disease, ocular GVHD, and corneal transplant complications, PROSE is often the ideal, and sometimes only, treatment capable of restoring visual function and reducing eye pain and light sensitivity, and all without surgery.

Join us on April 22nd, for a 1-hour informational webinar where BostonSight's Chief Medical Officer, Dr. Dan Brocks, and Clinic Director, Darlene Riordan, provide information about PROSE treatment and how to access it. You'll also hear from Bob, our PROSE patient representative.

Join us Wednesday, April 22nd, 2026
8:00 - 9:00 pm EDT

Register today: https://us02web.zoom.us/webinar/register/WN_yDxUJecLQneW8eWqaoOHFQ #/registration

Due to inclement weather, BostonSight will have a delayed opening until 10:00am EST on Tuesday, February 24th, 2026.Cust...
02/24/2026

Due to inclement weather, BostonSight will have a delayed opening until 10:00am EST on Tuesday, February 24th, 2026.

Customers contacting fitting consultancy may experience delays.

Due to inclement weather, BostonSight will be closed on Monday, February 23rd, 2026.Customers contacting fitting consult...
02/22/2026

Due to inclement weather, BostonSight will be closed on Monday, February 23rd, 2026.

Customers contacting fitting consultancy may experience delays.

BostonSight Unveils 5-Year Roadmap to Advance Scleral Lens Technology, Research, and EducationNeedham, Mass. – February ...
02/17/2026

BostonSight Unveils 5-Year Roadmap to Advance Scleral Lens Technology, Research, and Education

Needham, Mass. – February 17, 2026. BostonSight® today announced a transformative 5-year strategic roadmap aimed at redefining ocular surface treatment through groundbreaking advancements in clinical research, education, and specialty lens technology. The organization has designated key leadership roles to lead initiatives that accelerate innovation and collaboration, with the goal of positively impacting patient lives around the world.

Dr. Karen Carrasquillo, OD, PhD, FAAO, FSLS, FBCLA, BostonSight’s Chief Innovation and Education Officer and Andrew Heim, Chief Technology Officer, will spearhead BostonSight’s innovation and technology strategy. They will be joined in these initiatives by Chirag Patel, OD, FAAO, Director of Innovative Technologies, and Olga Tomashevskaya, Director of Engineering. BostonSight will seek to partner with scientific, engineering, and clinical communities worldwide to revolutionize the way specialty lens treatment is delivered through innovative platforms, tools, and education.

Mr. Heim joined BostonSight in 2025 as the organization’s first CTO, bringing more than 15 years of experience in software and technical development, including nearly a decade of leading high-performing technical teams.

“Andrew brings deep expertise in technology as well as a strong understanding of BostonSight’s mission and goals,” said Sara Yost, MBA, BostonSight President and CEO. “He will be dedicated to ensuring that BostonSight stays at the forefront of technological innovation, so we not only meet, but exceed, customer expectations.”

Mr. Heim’s focus includes aligning technology with business objectives, enhancing clinical decision-making through artificial intelligence, and ensuring a secure, scalable infrastructure that supports BostonSight’s growing global operations. He will be instrumental in upholding customer and partner trust through rigorous data protection practices and training. In addition, Mr. Heim and Dr. Carrasquillo will partner on leveraging technology to expand the global accessibility of BostonSight’s educational platforms.

In addition to being a PROSE® Provider, Dr. Patel explores the intersection of patient care with technology. His research of corneo-scleral data has advanced BostonSight’s data-driven scleral lens designs to improve fitting efficiency and effectiveness. In partnership with Ms. Tomashevskaya, Dr. Patel is also developing novel approaches to enhance lens optical properties.

“Our mission is driven by a simple yet powerful belief: everyone who needs a specialty lens—no matter where they are in the world—should have access to the best care and technology available,” said Ms. Yost. “By investing in these initiatives and empowering innovative leaders, we are shaping the future of specialty lens technology while supporting practitioners with the knowledge and skills to deliver meaningful change for their patients.”

https://www.bostonsight.org/bostonsight-unveils-5-year-roadmap-to-advance-scleral-lens-technology-research-and-education/

Please note BostonSight, including lab and consultation, will be closed on Monday, February 16th, 2026.
02/12/2026

Please note BostonSight, including lab and consultation, will be closed on Monday, February 16th, 2026.

Michelle Thezin Kong, OD, Joins BostonSight as PROSE ProviderNeedham, Mass. –February 3, 2026.  BostonSight® announced t...
02/03/2026

Michelle Thezin Kong, OD, Joins BostonSight as PROSE Provider

Needham, Mass. –February 3, 2026. BostonSight® announced today that Michelle Thezin Kong, OD, has joined BostonSight as its newest PROSE® Provider. Dr. Kong joins existing PROSE Providers, Drs. Bita Asghari, Karen Carrasquillo, Alan Kwok, and Chirag Patel.

Dr. Kong received her Doctor of Optometry from the University of California (UC) Berkeley and completed her residency with programs at the New England College of Optometry, the Massachusetts Eye and Ear Infirmary, BostonSight, and Andover Optometry on Central. Dr. Kong also completed clinical internships at the California School for the Blind, UC Berkeley Meredith Morgan Eye Center, the VA Palo Alto Health Care System, and West Oakland Health Center. Most recently, she practiced at Atrius Health, where she fit patients with specialty lenses.

“Welcoming Dr. Kong to our clinical team is incredibly exciting for BostonSight and for the patients we serve,” said Sara Yost, President and CEO of BostonSight. “By expanding our team, we’re able to meet the increasing demand for our specialized care, and Dr. Kong’s impressive training reflects the deep commitment to excellence in patient care that defines BostonSight.”

Dr. Kong is a GPLI Resident Advisory Board Member and is fluent in English and Burmese.

https://www.bostonsight.org/michelle-thezin-kong-od-joins-bostonsight-as-prose-provider/

Due to inclement weather, BostonSight will have a delayed opening until 12:00pm EST on Monday, January 26th, 2026.Custom...
01/26/2026

Due to inclement weather, BostonSight will have a delayed opening until 12:00pm EST on Monday, January 26th, 2026.

Customers contacting fitting consultancy may experience delays.

Please note BostonSight, including lab and consultation, will be closed on Thursday, January 19th, 2026.
01/15/2026

Please note BostonSight, including lab and consultation, will be closed on Thursday, January 19th, 2026.

Please note BostonSight, including lab and consultation, will be closed on Thursday, January 1st, 2026.
12/29/2025

Please note BostonSight, including lab and consultation, will be closed on Thursday, January 1st, 2026.

Please note that BostonSight, including lab and consultation, will be closed on Thursday & Friday, December 25 & 26, 202...
12/22/2025

Please note that BostonSight, including lab and consultation, will be closed on Thursday & Friday, December 25 & 26, 2025.

The National Keratoconus Foundation (NKCF) is conducting an anonymous survey to better understand the real-life challeng...
10/28/2025

The National Keratoconus Foundation (NKCF) is conducting an anonymous survey to better understand the real-life challenges faced by individuals with keratoconus and their caregivers. By sharing your experience, you’ll help us identify what truly improves quality of life—and what stands in the way—so we can shape our programs, resources, and advocacy to better serve our community.

Take the survey now: https://uci.questionpro.com/nkcf-survey

The survey is completely anonymous and takes just a few minutes to complete. As a thank you, participants will be entered into a drawing to win a $50 Amazon Gift Card.

Your voice matters—and it can make a lasting difference for thousands of people living with keratoconus.

Have you ever wondered about PROSE® treatment and how it might help you? PROSE (prosthetic replacement of the ocular sur...
09/04/2025

Have you ever wondered about PROSE® treatment and how it might help you? PROSE (prosthetic replacement of the ocular surface ecosystem) is a treatment pioneered by BostonSight. For thousands of patients suffering from the most complex ocular surface diseases, including keratoconus, dry eye disease, ocular GVHD, and corneal transplant complications, PROSE is often the ideal, and sometimes only, treatment capable of restoring visual function and reducing eye pain and light sensitivity, and all without surgery.

Join us on October 1 for a 1-hour informational webinar where BostonSight's Chief Medical Officer, Dr. Dan Brocks, and Clinic Director, Darlene Riordan, provide information about PROSE treatment and how to access it. You'll also hear from Kinney, at PROSE patient who has Sjögren's Syndrome.

Join us Wednesday, October 1, 2025
8:00 - 9:00 pm EDT

Register today - https://us02web.zoom.us/webinar/register/WN_4HMyUF6DRsuLKm2ymC6cHQ

Address

464 Hillside Avenue, Ste 205
Needham Heights, MA
02494

Opening Hours

Monday 7:30am - 5pm
Tuesday 7:30am - 5pm
Wednesday 7:30am - 5pm
Thursday 7:30am - 5pm
Friday 7:30am - 4pm

Telephone

+17817267337

Website

https://www.bostonsightscleral.org/

Alerts

Be the first to know and let us send you an email when BostonSight posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category